Spark Therapeutics (NASDAQ:ONCE) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, February 19th. Analysts expect Spark Therapeutics to post earnings of ($0.86) per share for the quarter.
NASDAQ:ONCE opened at $49.45 on Wednesday. Spark Therapeutics has a 52 week low of $34.53 and a 52 week high of $96.59. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.36 and a current ratio of 10.71. The company has a market cap of $1.81 billion, a PE ratio of -6.48 and a beta of 2.06.
A number of research firms have recently commented on ONCE. William Blair reiterated a “buy” rating on shares of Spark Therapeutics in a report on Tuesday, November 6th. Credit Suisse Group reiterated a “hold” rating and set a $44.00 price target on shares of Spark Therapeutics in a report on Friday, February 8th. Cantor Fitzgerald set a $103.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Monday, December 3rd. Raymond James reiterated a “buy” rating on shares of Spark Therapeutics in a report on Monday, November 26th. Finally, ValuEngine upgraded shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 1st. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. Spark Therapeutics has an average rating of “Buy” and a consensus target price of $65.20.
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Featured Article: QQQ ETF
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.